| Date | Title | Description | |
|---|---|---|---|
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 24 Jul 2025 | On P&L | The Company releases the first half 2025 financial results presentation | Download |
| 24 Jul 2025 | On P&L | The Company releases the press release related to the first half of 2025 financial results | Download |
| 25 Mar 2025 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2025 Capital Markets Day | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 10 May 2023 | Announcement of General Shareholders’ Meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 10 Apr 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2023 | Download |
| 21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
| 21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
| 16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |